Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.11B | 1.10B | 1.05B | 1.00B | 931.48M | 818.16M |
Gross Profit | 610.61M | 602.29M | 577.16M | 557.00M | 518.67M | 443.57M |
EBITDA | 415.84M | 442.20M | 406.83M | -17.41M | 400.81M | 319.96M |
Net Income | 24.82M | 44.40M | 51.38M | -233.57M | 116.88M | -38.62M |
Balance Sheet | ||||||
Total Assets | 3.10B | 3.07B | 3.13B | 3.12B | 2.79B | 2.76B |
Cash, Cash Equivalents and Short-Term Investments | 304.39M | 277.24M | 296.41M | 395.21M | 106.92M | 102.45M |
Total Debt | 2.35B | 2.35B | 2.33B | 2.03B | 1.83B | 1.91B |
Total Liabilities | 2.68B | 2.67B | 2.69B | 2.77B | 2.20B | 2.31B |
Stockholders Equity | 414.09M | 404.91M | 443.73M | 350.24M | 586.10M | 452.30M |
Cash Flow | ||||||
Free Cash Flow | 75.13M | 45.09M | -362.71M | 95.58M | 179.38M | 67.08M |
Operating Cash Flow | 239.22M | 224.16M | -147.73M | 277.96M | 281.55M | 120.58M |
Investing Cash Flow | -164.02M | -179.00M | -214.91M | -181.90M | -159.83M | -158.69M |
Financing Cash Flow | -15.95M | -50.56M | 265.96M | 197.76M | -117.29M | 73.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $3.67B | 22.99 | 18.83% | ― | 3.95% | 44.09% | |
66 Neutral | $3.32B | ― | -4.62% | ― | 7.19% | -56.19% | |
64 Neutral | $4.19B | ― | -19.71% | ― | -86.13% | -67.29% | |
64 Neutral | $4.56B | ― | -111.13% | ― | 20.54% | 25.73% | |
61 Neutral | $3.25B | 134.41 | 5.88% | ― | 2.78% | -54.72% | |
60 Neutral | $2.89B | ― | -10.43% | ― | 13.54% | -30732.00% | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% |
At its 2025 annual meeting on May 21, Sotera Health Company elected three Class II directors for a three-year term, approved executive compensation, and ratified Ernst & Young LLP as its independent auditor for 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (SHC) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.
On April 3, 2025, Sterigenics U.S., LLC, a subsidiary of Sotera Health Company, agreed to a settlement of $30,943,000 to resolve 97 ethylene oxide claims related to its former Willowbrook, Illinois facility. The settlement, which requires participation from all claimants and court approval, is not an admission of liability by Sterigenics and is expected to be finalized within 60 to 90 days, potentially impacting the company’s legal standing and stakeholder relations.